This company has been acquired
Reunion Neuroscience Past Earnings Performance
Past criteria checks 0/6
Reunion Neuroscience's earnings have been declining at an average annual rate of -68.5%, while the Biotechs industry saw earnings growing at 30% annually. Revenues have been growing at an average rate of 83.9% per year.
Key information
-68.5%
Earnings growth rate
-4.6%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 83.9% |
| Return on equity | -178.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Revenue & Expenses BreakdownBeta
How Reunion Neuroscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -38 | 13 | 13 |
| 31 Dec 22 | 5 | -74 | 39 | 11 |
| 30 Sep 22 | 5 | -68 | 40 | 9 |
| 30 Jun 22 | 5 | -57 | 39 | 9 |
| 31 Mar 22 | 0 | -18 | 11 | 7 |
| 31 Dec 21 | 1 | -20 | 13 | 6 |
| 30 Sep 21 | 1 | -22 | 13 | 5 |
| 30 Jun 21 | 1 | -24 | 13 | 4 |
| 31 Mar 21 | 1 | -23 | 13 | 4 |
| 31 Dec 20 | 0 | -16 | 9 | 3 |
| 30 Sep 20 | 0 | -9 | 6 | 2 |
| 30 Jun 20 | 0 | -5 | 4 | 1 |
| 31 Mar 20 | 0 | -3 | 3 | 0 |
Quality Earnings: REUN is currently unprofitable.
Growing Profit Margin: REUN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if REUN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare REUN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REUN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.6%).
Return on Equity
High ROE: REUN has a negative Return on Equity (-178.92%), as it is currently unprofitable.